Next-generation multiplex fluorescence immunohistochemistry methods offer new capabilities for scientists to explore the biology of disease within patient tissues.This webinar will focus on user experiences using the Ultivue InSituPlex fluorescence multiplex IHC platform and provide insight and examples of how this technology can be applied in a research setting.
Keith is a board-certified human anatomic pathologist with diverse achievements in research, drug/diagnostic development, and clinical investigation. Leading Ultivue’s Pathology and Biomarker Analytics team, he brings expertise in investigative pathology, multiplex microscopy and imaging, and digital pathology to our customers striving to realize the promise of personalized medicine. Most recently he was Senior Medical Director of Leica Biosystems, and prior to that he led and supported R&D, toxicology, biomarker, and clinical study teams in multiple therapeutic areas at Biogen and Novartis Institutes for BioMedical Research.
He earned a BS in Chemical Engineering from the University of Arizona, and MD and PhD in Molecular Biology from UCLA, where he discovered the molecular basis of DNA recognition by bHLH-PAS transcription factors. Following internship and residency in Anatomic Pathology and fellowships in Autopsy Pathology and Developmental Biology at Stanford, his research lab at UT Southwestern established the Naked cuticle (Nkd) gene family as critical feedback regulators of Wnt/-catenin signaling.
Richard is an experienced financial manager with more than thirty years of experience in finance, accounting, internal audit, financial planning and treasury roles. Richard was most recently the Vice President & Controller at Oxford Immunotec Global PLC where he was responsible for the global accounting, finance and treasury functions during their initial public offering, three acquisitions, a divestiture and sale of the company. Prior to Oxford Immunotec, he held Controller and other senior financial roles at several Medical Device and High Technology firms including Salient Surgical Technologies, Neurometrix and Teradyne.
Richard earned his BA in Economics from Trinity College, Hartford CT and his Master of Science in Management from MIT’s Sloan School of Management. He is a licensed Certified Public Accountant and a US Navy veteran.
Siobhan Desmond joined Ultivue in early 2021 as Head of People and Culture. Siobhan is responsible for leading the vision and development of the Human Resources strategy, including Talent Acquisition, Total Rewards, Leadership Development, Diversity and Engagement & Inclusion.
Siobhan is a business-focused, results oriented executive with over 20 years of experience in diverse industries. She is a leader who invests in designing & implementing successful HR strategies to create thriving, scalable cultures.
Siobhan holds a Master of Science in Human Resources and Adult Organizational Learning from Suffolk University as well as a Bachelor of Arts in English from Saint Anselm College. She has advised on boards, such as Veritas Community School and is passionate about life long learning.
Mike is a chemist/biologist with 15 years experience enabling innovative solutions in the biotechnology and diagnostics industries. He brings extensive experience in nucleic acid chemistry/enzymology, in situ biomolecule detection, multiplexed biomolecule analysis, and sequencing system development. Most recently he was Chief Scientist/Head of Genomics R&D at Beckman Coulter Life Sciences and previously consulted in varying capacities for both established and startup biotechnology companies.
Mike earned a BS in Microbiology and Cell Science and a PhD in Nucleic Acid Chemistry from the University of Florida, where he developed artificial genetic systems capable of replication and evolution. He was a NIH Ruth L. Kirschstein Postdoctoral Fellow at Harvard Medical School and a fellow at the Wyss Institute at Harvard where he developed multiplexed sequencing, in situ sequencing, and multiplexed synthetic biology technologies.
Barry Lynch has been Vice President of Sales since September 2020. He has significant leadership experience across a broad range of life science businesses, including histology, proteomics and diagnostics. Prior to joining Ultivue he was the Commercial Director (EMEA) with Advanced Cell Diagnostics. Barry began his career with Invitrogen in 1999 where he went on to lead commercial teams at the Europe and Asia Pacific regional level. He holds and honors degree in Biochemistry from the University of Dundee and a MSc in Biotechnology.
Mark Rees, PhD joined Ultivue’s executive team in January as Vice President of Corporate Development. Mark has 21+ years of leadership experience in Scientific Affairs and Business development within research and diagnostic markets. Most recently, Mark was instrumental in creating a diagnostic division for StatLab, launching a full portfolio of IHC reagents, automated staining platform as well as a patented reference standard control technology for tissue pathology. Previously Mark held leadership roles in commercial development, Scientific Affairs and R&D at Enzo Lifesciences, Leica Biosystems NA (Danaher) and Novocastra Laboratories.
He holds a PhD in Molecular Biology & Microbiology, MS in Industrial Microbiology and a BS (hons) in Biochemistry, graduating from Newcastle University Medical School, England UK
Sharon is Co-Founder, Partner of Northpond Ventures. Sharon is currently a board director at 908 Devices, Emulate, Isoplexis, Ultivue, and Vizgen. She was previously CFO of Sands Capital Management. Over her 15 years with Sands Capital, assets under management grew from $1.5 billion to $50 billion. Prior to Sands Capital, Sharon was a consultant at McKinsey & Company. Sharon has an MBA from Harvard Business School and a BA in Economics from Rice University. She is a CFA charterholder. Sharon is an advocate for financial literacy and her work has been featured nationally, including her two books, ON MY OWN TWO FEET: A Modern Girl’s Guide to Personal Finance and GET FINANCIALLY NAKED: How to Talk Money with your Honey.
Anna Pevzner is a Controller and Senior Director of Financial Planning & Analysis at Ultivue. Anna has nearly 20 years of finance experience in various positions across life sciences, technology, and advanced materials industries in public and venture capital-backed companies. Most recently Anna led finance function at Veloxint, where she supported fundraising and oversaw planning and accounting for the MIT-incubated advanced materials startup. Prior to Veloxint Anna was a Director of Financial Planning & Analysis at Syneos Health. Earlier in her career she held positions of increasing responsibility, including financial planning and analysis, manufacturing finance and accounting at Dolby Laboratories, Thermo Fisher Scientific and Pelephone Communications.
Anna holds an MBA degree from Carnegie Mellon University, Tepper School of Business and BA degree in Economics from Ben-Gurion University of the Negev.
